Production of lentiviral vectors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Mol Ther Methods Clin Dev Année : 2016

Production of lentiviral vectors

M. Hebben
C. Bovolenta
  • Fonction : Auteur

Résumé

Lentiviral vectors (LV) have seen considerably increase in use as gene therapy vectors for the treatment of acquired and inherited diseases. This review presents the state of the art of the production of these vectors with particular emphasis on their large-scale production for clinical purposes. In contrast to oncoretroviral vectors, which are produced using stable producer cell lines, clinical-grade LV are in most of the cases produced by transient transfection of 293 or 293T cells grown in cell factories. However, more recent developments, also, tend to use hollow fiber reactor, suspension culture processes, and the implementation of stable producer cell lines. As is customary for the biotech industry, rather sophisticated downstream processing protocols have been established to remove any undesirable process-derived contaminant, such as plasmid or host cell DNA or host cell proteins. This review compares published large-scale production and purification processes of LV and presents their process performances. Furthermore, developments in the domain of stable cell lines and their way to the use of production vehicles of clinical material will be presented.

Dates et versions

hal-02881002 , version 1 (25-06-2020)

Identifiants

Citer

O. W. Merten, M. Hebben, C. Bovolenta. Production of lentiviral vectors. Mol Ther Methods Clin Dev, 2016, 3, pp.16017. ⟨10.1038/mtm.2016.17⟩. ⟨hal-02881002⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More